{"id":13753,"date":"2024-11-20T14:18:59","date_gmt":"2024-11-20T06:18:59","guid":{"rendered":"https:\/\/flcube.com\/?p=13753"},"modified":"2024-11-20T14:20:32","modified_gmt":"2024-11-20T06:20:32","slug":"biogen-and-samsung-bioepis-win-ec-approval-for-opuviz-biosimilar-in-europe","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13753","title":{"rendered":"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe"},"content":{"rendered":"\n

US-based Biogen Inc. (NASDAQ: BIIB<\/a>) and South Korea’s Samsung Bioepis Co., Ltd. have jointly announced that they have received marketing approval from the European Commission (EC) for their Opuviz 40 mg\/mL solution for injection in a vial. This biosimilar product, a version of Bayer\/Regeneron\u2019s Eylea (aflibercept), is now approved for use in treating adult patients with various vision impairments, including neovascular (wet) age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).<\/p>\n\n\n\n

Samsung Bioepis’ Transition and Partnership with Biogen<\/strong>
Samsung Bioepis, initially a joint venture between Biogen and Samsung Biologics (KRX: 207940<\/a>) established in 2012, became a wholly owned subsidiary of the South Korean firm in 2022. This transition occurred when Samsung Biologics acquired Biogen\u2019s remaining shares in the company for USD 2.3 billion. The partnership between Samsung Bioepis and Biogen dates back to November 2019, with Biogen being granted commercialization rights to BYOOVIZ, a biosimilar of Novartis\u2019s Lucentis (ranibizumab), and Opuviz, also known as SB15 in the US, Canada, Europe, and other certain countries. <\/p>\n\n\n\n

Opuviz’s Approval in a Competitive Landscape<\/strong>
Opuviz\u2019s regulatory approval follows closely on the heels of the EC’s approval of Switzerland-headquartered Sandoz\u2019s (SWX: SDZ<\/a>) Afqlir, issued earlier this week. This marks a significant development in the competitive landscape of biosimilars for ophthalmic treatments in Europe.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Biogen Inc. (NASDAQ: BIIB) and South Korea’s Samsung Bioepis Co., Ltd. have jointly announced…<\/p>\n","protected":false},"author":1,"featured_media":13759,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,43,2218,993,15,2220,2217,747,886],"class_list":["post-13753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-biosimilars","tag-krx-207940","tag-nasdaq-biib","tag-product-approvals","tag-samsung-bioepis","tag-samsung-biologics","tag-sandoz","tag-swx-sdz"],"yoast_head":"\nBiogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Biogen Inc. (NASDAQ: BIIB) and South Korea's Samsung Bioepis Co., Ltd. have jointly announced that they have received marketing approval from the European Commission (EC) for their Opuviz 40 mg\/mL solution for injection in a vial. This biosimilar product, a version of Bayer\/Regeneron\u2019s Eylea (aflibercept), is now approved for use in treating adult patients with various vision impairments, including neovascular (wet) age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13753\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13753\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-20T06:18:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-20T06:20:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"660\" \/>\n\t<meta property=\"og:image:height\" content=\"370\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe\",\"datePublished\":\"2024-11-20T06:18:59+00:00\",\"dateModified\":\"2024-11-20T06:20:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753\"},\"wordCount\":241,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg\",\"keywords\":[\"Biogen\",\"Biosimilars\",\"KRX: 207940\",\"NASDAQ: BIIB\",\"Product approvals\",\"Samsung Bioepis\",\"Samsung Biologics\",\"Sandoz\",\"SWX: SDZ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13753#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13753\",\"name\":\"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg\",\"datePublished\":\"2024-11-20T06:18:59+00:00\",\"dateModified\":\"2024-11-20T06:20:32+00:00\",\"description\":\"US-based Biogen Inc. (NASDAQ: BIIB) and South Korea's Samsung Bioepis Co., Ltd. have jointly announced that they have received marketing approval from the European Commission (EC) for their Opuviz 40 mg\\\/mL solution for injection in a vial. This biosimilar product, a version of Bayer\\\/Regeneron\u2019s Eylea (aflibercept), is now approved for use in treating adult patients with various vision impairments, including neovascular (wet) age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13753\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg\",\"width\":660,\"height\":370,\"caption\":\"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13753#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe - Insight, China's Pharmaceutical Industry","description":"US-based Biogen Inc. (NASDAQ: BIIB) and South Korea's Samsung Bioepis Co., Ltd. have jointly announced that they have received marketing approval from the European Commission (EC) for their Opuviz 40 mg\/mL solution for injection in a vial. This biosimilar product, a version of Bayer\/Regeneron\u2019s Eylea (aflibercept), is now approved for use in treating adult patients with various vision impairments, including neovascular (wet) age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13753","og_locale":"en_US","og_type":"article","og_title":"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13753","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-20T06:18:59+00:00","article_modified_time":"2024-11-20T06:20:32+00:00","og_image":[{"width":660,"height":370,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13753#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13753"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe","datePublished":"2024-11-20T06:18:59+00:00","dateModified":"2024-11-20T06:20:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13753"},"wordCount":241,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=13753#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg","keywords":["Biogen","Biosimilars","KRX: 207940","NASDAQ: BIIB","Product approvals","Samsung Bioepis","Samsung Biologics","Sandoz","SWX: SDZ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13753#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13753","url":"https:\/\/flcube.com\/?p=13753","name":"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=13753#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=13753#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg","datePublished":"2024-11-20T06:18:59+00:00","dateModified":"2024-11-20T06:20:32+00:00","description":"US-based Biogen Inc. (NASDAQ: BIIB) and South Korea's Samsung Bioepis Co., Ltd. have jointly announced that they have received marketing approval from the European Commission (EC) for their Opuviz 40 mg\/mL solution for injection in a vial. This biosimilar product, a version of Bayer\/Regeneron\u2019s Eylea (aflibercept), is now approved for use in treating adult patients with various vision impairments, including neovascular (wet) age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13753#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13753"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=13753#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg","width":660,"height":370,"caption":"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13753#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/862cd56f-d206-4d8b-86fe-3a6cabe2be43.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13753"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13753\/revisions"}],"predecessor-version":[{"id":13762,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13753\/revisions\/13762"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/13759"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}